Press Releases

Date Title and Summary
Toggle Summary Kezar Life Sciences Announces Initiation of Clinical Study to Test a New Drug Product Formulation of KZR-616
SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the initiation of a Phase 1,
Toggle Summary Kezar Life Sciences to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences Strengthens Management Team, Appoints Celia Economides as Senior Vice President, Strategy and External Affairs
SOUTH SAN FRANCISCO, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Celia
Toggle Summary Kezar Life Sciences to Present at The BMO Prescriptions for Success Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief
Toggle Summary Kezar Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its third quarter 2018
Toggle Summary Kezar Life Sciences to Present at Jefferies 2018 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences , Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler , Chief
Toggle Summary Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced that John Fowler, Chief
Toggle Summary Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its second quarter 2018
Toggle Summary Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , June 25, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today the closing of its initial
Toggle Summary Kezar Life Sciences Announces Pricing of Initial Public Offering
SOUTH SAN FRANCISCO, Calif. , June 20, 2018 /PRNewswire/ --  Kezar Life Sciences, Inc. ( Nasdaq:KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced today that it has priced its initial